• Safety Review Committee approved progression to third dosing cohort
• Preclinical studies showed NYR-BI03 had neuroprotective and cardioprotective effects
• Final Phase I trial readouts expected in Q3 2025

Nyrada Inc. (ASX:NYR), a drug discovery and development company focused on Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, has provided an update on its Phase I clinical trial for its lead drug candidate NYR-BI03. The company has confirmed that the Safety Review Committee (SRC) has reviewed cumulative safety and pharmacokinetic data from the first and second cohorts in the clinical trial and raised no issues, enabling the trial to progress to the third cohort. Recruitment for the third cohort is currently in progress, and final Phase I trial readouts are expected in the third quarter of 2025. Nyrada is developing NYR-BI03, a small-molecule, first-in-class drug for neuroprotection and cardioprotection indications. Previous preclinical studies have shown that NYR-BI03 achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in a stroke study, and provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury, a leading cause of tissue damage when blood flow is restored to the heart after injury. The company also announced the results of a preclinical traumatic brain injury study which showed that NYR-BI03 provided a statistically significant neuroprotective effect.

Nyrada expects to complete the final Phase I trial readouts in the third quarter of 2025 and will provide regular updates throughout the trial.